Compare HOWL & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOWL | FLYX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 70.2M |
| IPO Year | 2021 | N/A |
| Metric | HOWL | FLYX |
|---|---|---|
| Price | $0.61 | $6.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | 878.0K | ★ 6.1M |
| Earning Date | 11-04-2025 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $362,955,000.00 |
| Revenue This Year | N/A | $28.47 |
| Revenue Next Year | N/A | $22.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.38 |
| 52 Week Low | $0.56 | $1.90 |
| 52 Week High | $2.38 | $8.88 |
| Indicator | HOWL | FLYX |
|---|---|---|
| Relative Strength Index (RSI) | 31.58 | 66.61 |
| Support Level | $0.62 | $3.08 |
| Resistance Level | $0.67 | $8.88 |
| Average True Range (ATR) | 0.05 | 0.66 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 12.39 | 53.71 |
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.